Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose escalation of a curcuminoid formulation.

Christopher D Lao1, Mack T Ruffin, Daniel Normolle

  • 1Division of Hematology-Oncology, Department of Internal Medicine, University of Michigan, 2150 CCGC, Ann Arbor, MI 48109-0930, USA. clao@umich.edu

BMC Complementary and Alternative Medicine
|March 21, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Dose Oxytocin Protocol Implementation and Postpartum Hemorrhage.

Obstetrics and gynecology·2026
Same author

Diagnostic Translational Considerations for Global Health Settings: Portable Detection of Human Papillomavirus for Cervical Cancer Screening in India.

JCO global oncology·2025
Same author

Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.

Journal for immunotherapy of cancer·2025
Same author

Serum profiling of the antibody response to HPV in women with or without abnormal cervical cytology undergoing cervical cancer screening.

Frontiers in immunology·2025
Same author

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update.

European journal of cancer (Oxford, England : 1990)·2025

High doses of curcumin, a turmeric extract, were well-tolerated in healthy volunteers. This suggests curcumin

Area of Science:

  • Pharmacology and Toxicology
  • Natural Products Chemistry

Background:

  • Curcumin, a pigment from turmeric, shows potential for cancer prevention.
  • Limited human studies exist on curcumin's pharmacology and toxicology.

Purpose of the Study:

  • To determine the maximum tolerated dose and safety of curcumin.
  • To investigate curcumin's effects in healthy human volunteers.

Main Methods:

  • A dose escalation study administering 500 to 12,000 mg of curcumin.
  • Standardized, uniformly milled curcumin (C3 Complex) was used.

Main Results:

  • 30% of subjects experienced minimal, non-dose-related toxicity.
  • Curcumin was not detected in serum at doses up to 8,000 mg.

Related Experiment Videos

  • Low levels were detected at 10,000-12,000 mg.

    • Conclusions:

    • Curcumin demonstrates excellent tolerance in high single oral doses.
    • Further research is warranted for its use as a long-term chemopreventive agent, potentially independent of systemic bioavailability.